Scalable Generation of Universal Platelets from Human Induced Pluripotent Stem Cells

DSpace/Manakin Repository

Scalable Generation of Universal Platelets from Human Induced Pluripotent Stem Cells

Citable link to this page

 

 
Title: Scalable Generation of Universal Platelets from Human Induced Pluripotent Stem Cells
Author: Feng, Qiang; Shabrani, Namrata; Thon, Jonathan N.; Huo, Hongguang; Thiel, Austin; Machlus, Kellie R.; Kim, Kyungho; Brooks, Julie; Li, Feng; Luo, Chenmei; Kimbrel, Erin A.; Wang, Jiwu; Kim, Kwang-Soo; Italiano, Joseph; Cho, Jaehyung; Lu, Shi-Jiang; Lanza, Robert

Note: Order does not necessarily reflect citation order of authors.

Citation: Feng, Q., N. Shabrani, J. Thon, H. Huo, A. Thiel, K. Machlus, K. Kim, et al. 2014. “Scalable Generation of Universal Platelets from Human Induced Pluripotent Stem Cells.” Stem Cell Reports 3 (5): 817-831. doi:10.1016/j.stemcr.2014.09.010. http://dx.doi.org/10.1016/j.stemcr.2014.09.010.
Full Text & Related Files:
Abstract: Summary Human induced pluripotent stem cells (iPSCs) provide a potentially replenishable source for the production of transfusable platelets. Here, we describe a method to generate megakaryocytes (MKs) and functional platelets from iPSCs in a scalable manner under serum/feeder-free conditions. The method also permits the cryopreservation of MK progenitors, enabling a rapid “surge” capacity when large numbers of platelets are needed. Ultrastructural/morphological analyses show no major differences between iPSC platelets and human blood platelets. iPSC platelets form aggregates, lamellipodia, and filopodia after activation and circulate in macrophage-depleted animals and incorporate into developing mouse thrombi in a manner identical to human platelets. By knocking out the β2-microglobulin gene, we have generated platelets that are negative for the major histocompatibility antigens. The scalable generation of HLA-ABC-negative platelets from a renewable cell source represents an important step toward generating universal platelets for transfusion as well as a potential strategy for the management of platelet refractoriness.
Published Version: doi:10.1016/j.stemcr.2014.09.010
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235139/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:13454781
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters